Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.70 |
| ▸ | PDE4A | P27815 | 7/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CFTR | P13569 | 2/20 | 0.59 |
| ▸ | PDE2A | O00408 | 2/20 | 0.59 |
| ▸ | PDE1A | P54750 | 2/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.59 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376703 | 0.85 | ADORA2A (0.59) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL383123 | 0.85 | ADORA2A (0.72) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1460828 | 0.85 | ADORA2A (0.59) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7466316 | 0.83 | ADORA2A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| Enprofylline SCHEMBL1817246 | 0.80 | PDE4A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10980302 | 0.80 | ADORA2A (0.72) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| Enprofylline SCHEMBL156402 | 0.80 | PDE4A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5515323 | 0.80 | ADORA2A (0.71) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7602847 | 0.78 | PDE4A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25834247 | 0.78 | PDE4A (0.68) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-4301770-A1 | LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF | Eli Lilly and Company (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-116496976-A | Method for differentiating islet beta cells by adipose-derived mesenchymal stem cells and islet beta cells | 广州四叶草健康科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-110960574-A | Preparation method and application of patchouli extract | 黑龙江八一农垦大学 | 2020-04-07 | — | — | CN | disclosed |
| EP-2484754-A1 | Novel method for the production of differentiated respiratory epithelial cells | Medizinische Hochschule Hannover (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-6979687-B1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | Chen, Ing-Jun (TW) | 2005-12-27 | — | — | US | disclosed |
| US-6979687-B1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | Chen, Ing-Jun (TW) | 2005-12-27 | — | — | US | disclosed |
| US-20050209243-A1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | Chen, Ing-Jun | 2005-09-22 | — | — | US | disclosed |
| EP-1432801-A2 | RECEPTORS AND MEMBRANE-ASSOCIATED PROTEINS | Incyte Genomics, Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2002063006-A2 | RECEPTORS AND MEMBRANE-ASSOCIATED PROTEINS | INCYTE GENOMICS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0193599-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-09-10 | — | — | EP | disclosed |
| WO-1986001724-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209243-A1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | PRKG1, PDE3A, GUCY1A1 | ADORA2A 1025/4885PDE4A 11/4885PDE4B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.